Skip to content

Conversation

@Kwan-Jenny
Copy link
Collaborator

This pull request adds the finalized Beamer presentation materials for the April 14th meeting, including:

  • Beamer_Antibody_Kinetics.qmd: Full 32-slide presentation in Quarto Beamer format
  • Beamer_Antibody_Kinetics.pdf: Compiled version for presentation
  • Slides incorporate feedback from Dr. Morrison on the antibody kinetics model in Chapter 2
  • Covers model equations, parameter interpretations, hierarchical prior structures, and proposed correlation modeling across biomarkers

Please let me know if you want me to change anything in here.

@Kwan-Jenny Kwan-Jenny requested a review from d-morrison April 15, 2025 00:44
@codecov
Copy link

codecov bot commented Apr 15, 2025

Codecov Report

All modified and coverable lines are covered by tests ✅

✅ All tests successful. No failed tests found.

@d-morrison d-morrison changed the title 04.14.25 Meeting Material: Beamer Presentation (Chapter 2 Model Revisions) Model description and upcoming additions Apr 15, 2025
@github-actions
Copy link
Contributor

github-actions bot commented Apr 15, 2025

📖 https://ucd-serg.github.io/serodynamics/preview/pr88
Preview documentation for this PR (at commit b18c735)

Copy link
Collaborator

@d-morrison d-morrison left a comment

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Looks good so far! See comments

Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Please don't track the pdf version

Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Don't track the .tex version either

Comment on lines 27 to 34
$$
\frac{dy}{dt} =
\begin{cases}
\mu_1 b(t), & t < t_1 \\
- \alpha y(t)^r, & t \ge t_1
\end{cases}
\quad \text{with }
\frac{db}{dt} = \mu_0 b(t) - c y(t) b(t)
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

before introducing this new revised model, can you summarize the Teunis 2016 and 2023 models?

@Kwan-Jenny Kwan-Jenny requested a review from d-morrison April 29, 2025 23:47
@Kwan-Jenny Kwan-Jenny removed the request for review from d-morrison May 7, 2025 01:07
@Kwan-Jenny Kwan-Jenny requested a review from sschildhauer May 16, 2025 01:04
@Kwan-Jenny Kwan-Jenny requested review from sschildhauer and removed request for sschildhauer May 22, 2025 23:27
@Kwan-Jenny
Copy link
Collaborator Author

image

Currently, there are three .qmd files in the articles folder, but Antibody_Kinetics.qmd is the most up-to-date version. Therefore, only Antibody_Kinetics.qmd needs to be reviewed. However, I am unsure whether I should delete the other two .qmd files. @d-morrison, should I delete the other two and keep only this one?

Copy link
Collaborator

@sschildhauer sschildhauer left a comment

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

This looks great Kwan! Just a few small clarifications. After reviewing you can re request from me and I will try to review in a more timely manner.

@@ -0,0 +1,250 @@
---
title: "Hierarchical Bayesian Model"
author: "Our Study Group"
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
author: "Our Study Group"
author: "Kwan Ho Lee, UC Davis SeroEpidemiology Research Group"


## Big Picture: What Are We Modeling?

We are modeling **how antibody levels change over time** in response to infection, using data from multiple individuals and multiple **biomarkers** (10 antigen-isotype combinations, so ( j = 1, 2, ..., 10 )).
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
We are modeling **how antibody levels change over time** in response to infection, using data from multiple individuals and multiple **biomarkers** (10 antigen-isotype combinations, so ( j = 1, 2, ..., 10 )).
We are modeling **how antibody levels change over time** in response to infection for different antigen-isotype (biomarker) combinations (ex. anti-LPS IgG), using longitudinal serologic data from multiple individuals (10 antigen-isotype combinations, so ( j = 1, 2, ..., 10 )).


## Big Picture: What Are We Modeling?

We are modeling **how antibody levels change over time** in response to infection, using data from multiple individuals and multiple **biomarkers** (10 antigen-isotype combinations, so ( j = 1, 2, ..., 10 )).
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Why is this 10 antigen-isotype combinations? Couldn't it technically be any number of combinations?

We want to:

- Understand the average pattern for each biomarker
- Allow each person’s response to vary
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
- Allow each person’s response to vary
- Allow each person’s response to vary as a random effect

\end{bmatrix}
$$

These describe the antibody curve for person ( $i$ ) and biomarker ( $j$ ): the starting level, how fast it rises, peaks, and decays.
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
These describe the antibody curve for person ( $i$ ) and biomarker ( $j$ ): the starting level, how fast it rises, peaks, and decays.
These describe the antibody kinetic curve for each person ( $i$ ) and biomarker ( $j$ ): the baseline antibody level, rate of increase, peaks antibody level, and decay (waning) rate.


Higher $\nu_j$ $\rightarrow$ more informative prior (stronger prior).

Lower $\nu_j$ $\rightarrow$ more weakly informative (broader prior or weaker prior).
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
Lower $\nu_j$ $\rightarrow$ more weakly informative (broader prior or weaker prior).
Lower $\nu_j$ $\rightarrow$ less informative (broader prior or weaker prior).


The model is built hierarchically across five conceptual levels:

1. **Observed data:** noisy log antibody concentrations from serum samples
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
1. **Observed data:** noisy log antibody concentrations from serum samples
1. **Observed data:** log antibody concentrations from serum samples

The model is built hierarchically across five conceptual levels:

1. **Observed data:** noisy log antibody concentrations from serum samples
2. **Latent individual parameters:** hidden antibody dynamics $\theta_{ij}$ for each subject-biomarker pair
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

What does "hidden" mean here? Does it mean unobserved?


2. **Middle Level**:

- For each person $i$, their parameters:
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
- For each person $i$, their parameters:
- Each person $i$ has their parameters:


3. **Bottom Level**:

- Their actual observed antibody levels are noisy measurements of predictions from $\theta_{ij}$:
Copy link
Collaborator

Choose a reason for hiding this comment

The reason will be displayed to describe this comment to others. Learn more.

Suggested change
- Their actual observed antibody levels are noisy measurements of predictions from $\theta_{ij}$:
- Observed antibody levels are noisy measurements of predictions from $\theta_{ij}$:

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment

Labels

None yet

Projects

None yet

Development

Successfully merging this pull request may close these issues.

4 participants